Executive Wealth Management’s Royalty Pharma RPRX Stock Holding History

Executive Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-74,700	Closed	-$2.11M	–	271
2024 Q3	$2.11M	Sell	74,700 -22,839	-23%	-$633K	0.17%	113
2024 Q2	$2.57M	Buy	97,539 +4,583	+5%	+$127K	0.47%	47
2024 Q1	$2.78M	Buy	92,956 +37,043	+66%	+$1.09M	0.24%	91
2023 Q4	$1.57M	Buy	55,913 +4,886	+10%	+$134K	0.15%	109
2023 Q3	$1.38M	Buy	51,027 +8,755	+21%	+$260K	0.14%	110
2023 Q2	$1.3M	Buy	42,272 +21,682	+105%	+$734K	0.13%	113
2023 Q1	$742K	Buy	+20,590	New	+$763K	0.08%	128

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Executive Wealth Management's RPRX Position: Q4 2024 in Review

Executive Wealth Management sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 74,700 shares — an estimated $2.11M sold.

Executive Wealth Management first reported a position in RPRX in Q1 2023 and held it in 7 quarters. The position peaked at $2.78M in Q1 2024. 416 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

Executive Wealth Management reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
Executive Wealth Management sold 74,700 Royalty Pharma shares in Q4 2024, an estimated $2.11M.
Executive Wealth Management first reported a position in Royalty Pharma in Q1 2023 and held it in 7 quarters.
Executive Wealth Management's Royalty Pharma position peaked at $2.78M in Q1 2024.
416 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Executive Wealth Management's 13F filing for Q4 2024, filed 13 Feb 2025.